Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2020

01-09-2020 | Metastasis | Research Article

DT-13 inhibits breast cancer cell migration via non-muscle myosin II-A regulation in tumor microenvironment synchronized adaptations

Authors: Y. Gao, G. J. Khan, X. Wei, K.-F. Zhai, L. Sun, S. Yuan

Published in: Clinical and Translational Oncology | Issue 9/2020

Login to get access

Abstract

Background

Tumor metastasis is a terrifying characteristic of cancer. Numerous studies have been conducted to overcome metastasis by targeting tumor microenvironment (TME). However, due to complexity of tumor microenvironment, it remained difficult for accurate targeting. Dwarf-lillytruf tuber monomer-13 (DT-13) possess good potential against TME.

Objective

As TME is supportive for tumor metastasis, alternatively it is a challenging for therapeutic intervention. In our present study, we explored molecular mechanism through which TME induced cell migration and how DT-13 interferes in this mechanism.

Methods

We used a novel model of co-culture system which is eventually developed in our lab. Tumor cells were co-cultured with hypoxia induced cancer-associated fibroblasts (CAF) or with chemically induced cancer-associated adipocytes (CAA). The effect of hypoxia in conditioned medium for CAF was assessed through expression of α-SMA and HIF by western blotting while oil red staining was done to assess the successful chemical induction for adipocytes (CAA), the effect of TME through conditioned medium on cell migration was analyzed by trans-well cell migration, and cell motility (wound healing) analyses. The expression changes in cellular proteins were assessed through western blotting and immunofluorescent studies.

Results and conclusion

Our results showed that tumor microenvironment has a direct role in promoting breast cancer cell migration by stromal cells; moreover, we found that DT-13 restricts this TME regulated cell migration via targeting stromal cells in vitro. Additionally we also found that DT-13 targets NMII-A for its effect on breast cancer cell migration for the regulation of stromal cells in TME.
Literature
1.
Khan GJ, et al. Understanding and responsiveness level about cervical cancer and its avoidance among young women of Pakistan. Asian Pac J Cancer Prev. 2014;15(12):4877–83.PubMed
2.
Subramani R, et al. Role of growth hormone in breast cancer. Endocrinology. 2017;158(6):1543–55.PubMed
3.
Hanahan D, Awada A. The hallmarks of cancer revisited. Ann Oncol. 2012;100(1):57–70.
4.
Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19(11):1450.PubMed
5.
Wang X et al. interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma. Cytokine. 2018;103:150–9.
6.
Yang T, et al. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Drug Discov Today. 2019;24(1):112–28.PubMed
7.
Michiels C, C Tellier, O Feron. Cycling hypoxia: a key feature of the tumor microenvironment. Biochim Biophys Acta (BBA) Rev Cancer. 2016; 1866(1):76–86.
8.
Huyen CTT, et al. Chemical constituents from Cimicifuga dahurica and their anti-proliferative effects on MCF-7 breast cancer cells. Molecules. 2018;23(5):1083.PubMedCentral
9.
10.
Orimo A, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.PubMed
11.
Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32(4):550–70.PubMedPubMedCentral
12.
13.
Kuzet SE, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res. 2016;365(3):607–19.PubMed
14.
Hugo HJ, et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) il-6 effects within the tumor microenvironment. Cancer Microenviron. 2012;5(1):83–93.PubMedPubMedCentral
15.
Ghulam Jilany K, et al. Versatility of cancer associated fibroblasts: commendable targets for anti-tumor therapy. Curr Drug Targets. 2018;19(13):1573–88.
16.
Ammirante M, et al. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA. 2014;111(41):14776.PubMedPubMedCentral
17.
Dirat B, et al. 495 Cancer-associated adipocytes exhibit an activated phenotype and contribute to early breast cancer invasion in vitro and in vivo. Eur J Cancer Suppl. 2010;8(5):126.
18.
Nieman KM, et al. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831(10):1533.PubMedPubMedCentral
19.
20.
Du H, et al. DT-13 inhibits cancer cell migration by regulating NMIIA indirectly in the tumor microenvironment. Oncol Rep. 2016;36(2):721–8.PubMed
21.
Ghulam Jilany K, et al. TGF-β1 causes emt by regulating N-acetyl glucosaminyl transferases via downregulation of non muscle myosin II-A through jnk/p38/pi3k pathway in lung cancer. Curr Cancer Drug Targets. 2017;17:1–11.
22.
Ghulam Jilany K, et al. In-vitro pre-treatment of cancer cells with Tgf-β1: a novel approach of tail vein lung cancer metastasis mouse model for anti-metastatic studies. Curr Mol Pharmacol. 2019;12(4):249–60.
23.
Wei XH, et al. DT-13 attenuates human lung cancer metastasis via regulating NMIIA activity under hypoxia condition. Oncol Rep. 2016;36(2):991–9.PubMed
24.
Evenram S, et al. Myosin IIA regulates cell motility and actomyosin–microtubule crosstalk. Nat Cell Biol. 2007;9(3):299–309.
25.
Zhang Y, et al. DT-13 suppresses MDA-MB-435 cell adhesion and invasion by inhibiting MMP-2/9 via the p38 MAPK pathway. Mol Med Rep. 2012;6(5):1121.PubMed
26.
Sen-Sen L, et al. The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis. Chin J Nat Med. 2014;12(11):833.
27.
28.
Khan GJ, et al. Pharmacological effects and potential therapeutic targets of DT-13. Biomed Pharmacother. 2018;97:255–63.PubMed
29.
Af S, et al. Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science. 2003;299(5613):1743–7.
30.
Le CC, Carlier MF. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev. 2008;88(2):489.
31.
Dahan I, et al. The tumor suppressor Lgl1 regulates NMII-A cellular distribution and focal adhesion morphology to optimize cell migration. Mol Biol Cell. 2012;23(4):591.PubMedPubMedCentral
32.
Tang DD, Gerlach BD. The roles and regulation of the actin cytoskeleton, intermediate filaments and microtubules in smooth muscle cell migration. Respir Res. 2017;18(1):54.PubMedPubMedCentral
33.
Stricker J, Falzone T, Gardel ML. Mechanics of the F-actin cytoskeleton. J Biomech. 2010;43(1):9–14.PubMed
34.
Peng X, et al. Vinculin regulates cell-surface E-cadherin expression by binding to beta-catenin. J Cell Sci. 2010;123(4):567–77.PubMedPubMedCentral
35.
Small JV, et al. How do microtubules guide migrating cells? Nat Rev Mol Cell Biol. 2002;3(12):957.PubMed
36.
Jannie KM, et al. Vinculin-dependent actin bundling regulates cell migration and traction forces. Biochem J. 2015;465(3):383–93.PubMed
37.
Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117(20):4619.PubMed
38.
Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005;6(11):827–37.PubMed
39.
Sun L, et al. The saponin monomer of dwarf lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor. Biol Pharm Bull. 2010;33(7):1192.PubMed
40.
Lin SS, et al. The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis. Chin J Nat Med. 2014;12(11):833.PubMed
41.
Yu XW, et al. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptorin vitro and in vivo. Oncotarget. 2016;7(22):32990.PubMedPubMedCentral
42.
Li H, et al. DT-13, a saponin monomer of dwarf lilyturf tuber, induces autophagy and potentiates anti-cancer effect of nutrient deprivation. Eur J Pharmacol. 2016;781:164–72.PubMed
43.
Raval RR, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675.PubMedPubMedCentral
44.
Gordan JD, et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14(6):435.PubMedPubMedCentral
45.
Muz B, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83.PubMedPubMedCentral
46.
Leszczynska KB, et al. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest. 2015;125(6):2385–98.PubMedPubMedCentral
47.
Lim H, Moon A. Inflammatory fibroblasts in cancer. Arch Pharmacal Res. 2016;39(8):1–11.
48.
Rio MC, Dali-Youcef N, Tomasetto C. Local adipocyte cancer cell paracrine loop: can “sick fat” be more detrimental? Horm Mol Biol Clin Investig. 2015;21(1):43–56.PubMed
49.
Zhao B, et al. Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-β1/Smad3 pathway. Int J Mol Med. 2016;39(1):153–9.PubMedPubMedCentral
50.
Ghulam Jilany K, et al. TGF-β1 causes EMT by regulating N-Acetyl Glucosaminyl transferases via downregulation of non muscle myosin II-A through JNK/P38/PI3K pathway in lung cancer. Curr Cancer Drug Targets. 2018;18(2):209–19.
51.
Yaoborengasser A, et al. Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells. Oncol Rep. 2015;33(6):2689–94.
52.
Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res. 2006;66(9):4725–33.PubMed
53.
Jacobelli J, et al. Confinement-optimized three-dimensional T cell amoeboid motility is modulated via myosin IIA-regulated adhesions. Nat Immunol. 2010;11(10):953.PubMedPubMedCentral
54.
Morin NA, et al. Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration. J Exp Med. 2008;205(1):195.PubMedPubMedCentral
55.
Tanaka C, et al. GADD34 suppresses wound healing by upregulating expression of myosin IIA. Transgenic Res. 2010;19(4):637–45.PubMed
56.
Babbin BA, Koch S, Bachar M, Conti MA, Parkos CA, Adelstein RS, Nusrat A, Ivanov AI. Non-muscle myosin IIA differentially regulates intestinal epithelial cell restitution and matrix invasion. Am J Pathol. 2009;174(2):436.PubMedPubMedCentral
Metadata
Title
DT-13 inhibits breast cancer cell migration via non-muscle myosin II-A regulation in tumor microenvironment synchronized adaptations
Authors
Y. Gao
G. J. Khan
X. Wei
K.-F. Zhai
L. Sun
S. Yuan
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02303-z

Other articles of this Issue 9/2020

Clinical and Translational Oncology 9/2020 Go to the issue

Research Article

DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome

Research Article

Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression

Research Article

RNF213 suppresses carcinogenesis in glioblastoma by affecting MAPK/JNK signaling pathway

Review Article

Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

Review Article

Genomic profiling in oncology clinical practice

Research Article

Prognostic significance of sentinel node biopsy status in cutaneous melanoma: a 21-years prospective study from a single institution
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits